Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

21. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials (Abstract)

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end (...) point was the percentage of overall responders (patients reporting ≥30% reduction from baseline in worst abdominal pain plus an increase of ≥1 complete spontaneous bowel movement (CSBM)/week from baseline in the same week for ≥6 of 12 treatment weeks). Safety was assessed by adverse events (AEs).Overall, 2189 individuals were randomized across the two studies and 1879 completed the studies. Demographic and baseline characteristics were similar across treatment groups and between studies

2018 EvidenceUpdates

22. Irritable bowel syndrome

be individualised and is dependent on the patient's predominant symptoms. Definition Irritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain associated with bowel dysfunction. The pain is often relieved by defecation and is sometimes accompanied by abdominal bloating. There are no structural abnormalities to explain the pain. IBS occurs in about 15% of the adult population. The aetiology is probably multi-factorial and evidence suggests motility, inflammatory, genetic, immune (...) , psychological, and dietary components. Drossman DA, Camilleri M, Mayes FA. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31. http://www.ncbi.nlm.nih.gov/pubmed/12454866?tool=bestpractice.com History and exam presence of risk factors abdominal discomfort alteration of bowel habits associated with pain abdominal bloating or distension normal examination of abdomen passage of mucus with stool physical and sexual abuse age <50 years female sex previous enteric

2018 BMJ Best Practice

23. Viberzi - eluxadoline - Irritable bowel syndrome with diarrhea

and drug plans August 24, 2018 CDEC Final Recommendation posted August 29, 2018 Final CDR review report(s) and patient input posted September 18, 2018 Tags digestive system, gastrointestinal tract, diarrhea, irritable bowel syndrome, irritable bowel; Diarrhea Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Viberzi - eluxadoline - Irritable bowel syndrome with diarrhea eluxadoline | CADTH.ca Find the information you need eluxadoline eluxadoline Last Updated: September 18, 2018 Result type: Reports Project Number: SR0560-000 Product Line: Generic Name: eluxadoline Brand Name: Viberzi Manufacturer: Allergan Pharma Co. Indications: Irritable bowel syndrome with diarrhea Manufacturer Requested Reimbursement Criteria 1 : As per the Health Canada-approved indication (for the tretment of irritable bowel

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

24. Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Full Text available with Trip Pro

Self-Perception of Iranian Patients during their life with Irritable Bowel Syndrome: A Qualitative Study Irritable bowel syndrome (IBS), as a chronic digestive disorder, impacts extensively on the quality of life, emotional well-being and self-identity. Chronic illness disrupts taken-for-granted notions about self. No qualitative study was found regarding patients' experience of life with irritable bowel syndrome (IBS) in Iran.To explore the self-perception of lived experience of IBS patients.A

2017 Electronic physician

25. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial Full Text available with Trip Pro

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS.We performed a 2×2 factorial trial of 104 (...) number of staple and non-staple foods as the low FODMAP diet; the diets had similar degrees of difficulty to follow. Dietary counselling was given to patients in all groups and data on foods eaten and compliance were collected. The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were measured daily for 7 days before the study period; along with stool frequency and consistency. At baseline, global and individual symptoms were measured, along with generic and disease

2017 EvidenceUpdates

26. Eluxadoline for treating irritable bowel syndrome with diarrhoea

, having considered evidence on the nature of irritable bowel syndrome with diarrhoea (IBS-D) and the value placed on the benefits of eluxadoline by people with the condition, those who represent them, and clinical experts. It also took into account the effective use of NHS resources. Nature of the condition 4.2 The committee was aware of the experiences of people with IBS-D. It heard that IBS-D is diagnosed after physicians rule out other conditions, including inflammatory bowel disease, colorectal (...) it appropriate to stop. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 242 2 The technology The technology Description of Description of the technology the technology Eluxadoline (Truberzi, Allergan) is an opioid receptor agonist and delta-opioid receptor antagonist that binds to opioid receptors in the digestive system and slows down the movement

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

27. Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial Full Text available with Trip Pro

Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial IBS is the most common functional disease of the low gastrointestinal tract. Recently, the interest towards a diet approach has increased, for example, a diet with low content of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs). The aim of the present study

2017 Journal of translational internal medicine Controlled trial quality: uncertain

28. Irritable Bowel Syndrome. (Abstract)

Irritable Bowel Syndrome. This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions

2017 Annals of Internal Medicine

29. Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial (Abstract)

Home-Based Hypnotherapy Self-exercises vs Individual Hypnotherapy With a Therapist for Treatment of Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, or Functional Abdominal Pain Syndrome: A Randomized Clinical Trial Individual gut-directed hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal pain or functional abdominal pain syndrome (FAP[S]). It is, however, unavailable to many children.To compare the effectiveness of HT by means

2017 EvidenceUpdates

30. Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop Full Text available with Trip Pro

Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders—an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop A working theoretical model for irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGIDs) does not exist, hampered by the lack of any clear cut invention that address all symptom and signs of the disease. Reports of cessation of symptom and signs of both major types

2017 Translational gastroenterology and hepatology

31. The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. Full Text available with Trip Pro

The mind-body connection in irritable bowel syndrome: A randomised controlled trial of hypnotherapy as a treatment. Hypnotherapy has been reported as being beneficial in the treatment of irritable bowel syndrome (IBS). We aimed to test the hypothesis that patients with IBS treated 'holistically' by hypnosis (i.e. by combined psychological and physiological symptom imagery) would have greater improvement in their IBS symptoms than patients treated by hypnosis using standard 'gut-directed (...) ' hypnotherapy, and both would be superior to simple relaxation therapy.Patients (n = 51) with Rome II criteria were randomised to 'individualised' (holistic) hypnotherapy, standard 'gut-directed' hypnotherapy or relaxation therapy for a period of 11 weeks with two follow-up assessments at 2 weeks and at 3 months after the completion of the trial. The primary outcome was bowel symptom severity scale (BSSS).All the participants in this study improved their IBS symptoms (pain, bloating, constipation

2017 Health psychology open Controlled trial quality: uncertain

35. Irritable bowel syndrome

Irritable bowel syndrome Irritable bowel syndrome - NICE CKS Share Irritable bowel syndrome: Summary Irritable bowel syndrome (IBS) is a chronic, relapsing, and often lifelong disorder of the lower gastrointestinal tract, with no discernible structural or biochemical cause. Typical clinical features are abdominal pain: Associated with a change in stool form and/or frequency. Which may be related to defaecation, and there may be associated bloating. The exact underlying cause of IBS is unknown (...) . [ ] Background information Background information Definition What is it? Irritable bowel syndrome (IBS) is a chronic, relapsing, and often lifelong disorder of the lower gastrointestinal tract, with no discernible structural or biochemical cause. Typical clinical features are abdominal pain: Associated with a change in stool form and/or frequency. Which may be related to defaecation, and there may be associated bloating. IBS may be classified by the predominant stool type according to the Rome IV criteria

2017 NICE Clinical Knowledge Summaries

36. Truberzi (eluxadoline) - for the treatment of adults who have irritable bowel syndrome with diarrhoea

index BSS Bristol Stool Scale CHMP Committee for Medicinal Products for Human Use Cmax maximum observed plasma concentration CNS central nervous system CSR clinical study report EMA European Medicines Agency EU European Union FDA US Food and Drug Administration GERD gastroesophageal reflux disease GI gastrointestinal IBS irritable bowel syndrome IBS-d diarrhea-predominant irritable bowel syndrome IBS-m irritable bowel syndrome, where a mixture of constipation and diarrhea is predominant IBS-QoL (...) discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Truberzi. Assessment report EMA/549473/2016 Page 8/108 2. Scientific discussion 2.1. Introduction Problem statement Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal problem characterised primarily by intestinal pain and/or discomfort and associated alterations of defecation and/or bowel habit. Associations with other symptoms are regularly present, such as abdominal distension

2016 European Medicines Agency - EPARs

37. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women Full Text available with Trip Pro

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron (...) consistency (40.8%; 95% CI, 35.1%-46.6%) than in the placebo group (24.3%; 95% CI, 19.4%-29.7%)--a difference of 16.5% (95% CI, 8.9%-24.0%; P < .001). Patients receiving ramosetron had significant reductions in abdominal pain and discomfort (P = .001) and greater improvement in QOL (P = .002) compared with placebo. Ramosetron induced constipation in 11.0% of patients.In a randomized, placebo-controlled study of 576 women with IBS-D, 2.5 μg ramosetron per day reduced symptoms and increased stool

2016 EvidenceUpdates Controlled trial quality: predicted high

38. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome Full Text available with Trip Pro

Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome Irritable bowel syndrome (IBS) affects a large number of children throughout the world. The symptom expression of IBS is heterogeneous, and several factors which may be interrelated within the IBS biopsychosocial model play a role. These factors include visceral hyperalgesia, intestinal permeability, gut microbiota, psychosocial distress, gut inflammation, bile acids, food intolerance, colonic bacterial

2016 Molecular and cellular pediatrics

39. Genetics of irritable bowel syndrome Full Text available with Trip Pro

Genetics of irritable bowel syndrome Irritable bowel syndrome (IBS) is a common condition with a complex and largely unknown etiology. There is no cure, and treatment options are mainly directed to the amelioration of symptoms. IBS causes reduced quality of life and poses considerable repercussions on health and socioeconomic systems. There is a heritable component in IBS, and genetic research is a valuable tool for the identification of causative pathways, which will provide important insight (...) into the pathophysiology. However, although some gene-hunting efforts have been conducted and a few risk genes proposed, IBS genetic research is lagging behind compared to other complex diseases. In this mini-review, we briefly summarize existing genetic studies, discuss the main challenges in IBS genetic research, and propose strategies to overcome these challenges for IBS gene discovery.

2016 Molecular and cellular pediatrics

40. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. Full Text available with Trip Pro

Eluxadoline for Irritable Bowel Syndrome with Diarrhea. Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist), in patients with IBS with diarrhea. Methods We randomly assigned 2427 adults who had IBS with diarrhea to eluxadoline (at a dose (...) of 75 mg or 100 mg) or placebo twice daily for 26 weeks (IBS-3002 trial) or 52 weeks (IBS-3001 trial). The primary end point was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of the days from weeks 1 through 12 and from weeks 1 through 26. Results For weeks 1 through 12, more patients in the eluxadoline groups (75 mg and 100 mg) than in the placebo group reached the primary end point (IBS

2016 NEJM Controlled trial quality: predicted high